TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04123158

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth \>30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; Cooked aspect; \]

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth \>30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; Cooked aspect; \]

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Intervention: Diagnostic Test Ultrasound Ultrasound investigating the following characteristics: Maximum size of the lesion ≥ 8cm; Largest diameter rapid growth (Growth \>30% per year); Irregular margins of the lesion; Presence of irregular cystic areas; Absence of acoustic shadow; Color Score 4; Cooked aspect; \]

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Diagnostic Test: MRI; MRI investigating the following carachteristics:~TARGET LESION Maximum diameter; Borders; Signal intensity on T2WI; Heterogeneity on T2WI; Cystic alteration(s); Cystic alteration(s) borders; Hemorrhage; T2 dark area(s); Flow voids; Signal intensity on DWI(b-1000); ADC value; ≥ 1,23 Signal intensity on contrasted images Intensity \[relative to myometrium\] (Hyper- / Hypo- / Iso- intense) Heterogeneity (Homogeneous / Heterogeneous) Unenhanced area(s) Presence (Present / Absent) Location (Central / None or non-central) 1 Tumour - myometrium contrast ratio on T2WI \[SItumour - SImyometrium / SImyometrium\]
Study: NCT01262976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular, 2 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's investigational vaccine 692342
Description: Intramuscular, 2 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Intramuscular, 2 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Intramuscular, 2 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Intramuscular, 2 doses
Study: NCT02769728

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier
Description: implantation of a duodeno-jejunal bypass liner for weight reduction in obese subjects with type 2 diabetes mellitus
Study: NCT00266253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses, po bid or qd for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses, po bid or qd for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses, po bid or qd for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses, po bid or qd for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GK Activator (2)
Description: Escalating doses, po bid or qd for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed, for 12 weeks
Study: NCT00783484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc +PF-03716539
Description: Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
Study: NCT00266253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: As prescribed, for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: As prescribed, for 12 weeks
Study: NCT03489798

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 6 misoprostol
Description: Up to 6 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3 misoprostol
Description: Up to 3 doses of 25ug of misoprostol applied every 6 hours. End point is cervical Bishop score \> 6.
Study: NCT01726088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
Study: NCT03624946

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zika Virus Immune Globulin (ZIKV-IG)
Description: Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a normal saline solution (0.9% sodium chloride).
Study: NCT03838224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dry needling
Description: Participants allocated in this group will receive a single session of dry needling of the obliquus capitis inferior. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The needle was shown to the participant before the intervention. Participants will be requested to lie in prone on the plinth. Participants' skin will be sterilized with antiseptic spray for the skin. The therapist will clean his hands and use sterilized gloves. The needle will be moved up and down within the muscle, using a fast-in and fast-out technique. Needle insertions will be repeated 12 times.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: Sham needling has shown to be a valid control method in dry needling research. The procedure in the sham group will be the same as the experimental group to guarantee the participants' blinding. Prior to the intervention, participants will receive information about the procedure and will be free to withdraw. The sham needle (same appearance/material as the true needle) was shown to the participant before the intervention to guarantee the blinding.
Study: NCT04853628

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alerta Alcohol
Description: The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different tailored text messages. Moreover, several gamification strategies are used (i.e. offering a challenge, giving different stories and the use of avatars in these stories that take place in three different scenarios: at home, at celebrations and in public places).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alerta Alcohol 2.0
Description: The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and BD, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject BD. This information is presented through different animated videos. Moreover, new gamification strategies are added (i.e. giving rewards and allocating points that can be accumulated and shown in a progress ranking) to those already used in Alerta Alcohol.
Study: NCT04126655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arfolitixorin
Description: Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arfolitixorin
Description: Per operative administration of 5-FU with Arfolitixorin or Calciumfolinate
Study: NCT03711604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenalisib
Description: BID Orally
Study: NCT02482155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: ibuprofen 400 mg single dose oral solution
Study: NCT00448708

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vascular Wrap Paclitaxel-Eluting Mesh
Description: 0.9 µg/mm\^2 paclitaxel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lifespan® ePTFE Vascular Graft
Description: vascular graft

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Lifespan® ePTFE Vascular Graft
Description: vascular graft
Study: NCT00928421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polidocanol Endovenous Microfoam 0.125%
Description: Polidocanol Endovenous Microfoam 0.125%, single dose
Study: NCT02198248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
Study: NCT03366805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Management Patient Education Video
Description: Patient education video that were created in-house specifically for this project.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Wound Care Patient Education Video
Description: Patient education video that were created in-house specifically for this project.
Study: NCT02198248

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucocorticoids
Description: Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucocorticoids
Description: Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.~High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule.
Study: NCT00150098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced HIV risk reduction and HIV vaccine education
Study: NCT03359135

Intervention type: OTHER
Intervention: Rehabilitation
Description: Rehabilitation during 4 weeks

Intervention type: OTHER
Intervention: Rehabilitation
Description: Rehabilitation during 4 weeks

Intervention type: DEVICE
Intervention: Compression Garment
Description: Rehabilitation associated to wearing CG during 4 weeks
Study: NCT04319900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: favipiravir tablets+chloroquine phosphatetablets tablets
Description: Favipiravir tablets+ chloroquine phosphate tablets group: 50 patients (anticipated).~Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.~Chloroquine phosphate tablets: a total of 1000mg split into two times on day one; from day two to day three, 500mg, once a day; from day four to day ten, 250mg, once a day. Maximum of 10 days for oral administration of the drug.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Favipiravir tablets
Description: Favipiravir tablets group: 50 patients (anticipated). Favipiravir tablets: On the first day, once for 1600 mg, twice a day; From the 2nd day to the 10th day, once for 600 mg, twice a day; maximum of 10 days for oral administration of the drug.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for favipiravir tablets is produced by Zhejiang Haizheng pharmaceutical co, LTD, batch no. 21812252, Placebo for chloroquine phosphate tablets is produced by the Chinese people's liberation army academy of military science military medical research institute production, batch no. 20200215. All placebos were complied with the quality inspection standard.
Study: NCT01208090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800
Description: ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-128800
Description: ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
Study: NCT01056445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: valsalva maneuver
Description: valsalva maneuver after carotid stenting

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: valsalva maneuver
Description: valsalva maneuver after carotid stenting
Study: NCT02714114

Intervention type: OTHER
Intervention: First-void urine collection
Description: One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).

Intervention type: OTHER
Intervention: First-void urine collection
Description: One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).

Intervention type: OTHER
Intervention: Blood draw
Description: One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).

Intervention type: OTHER
Intervention: Blood draw
Description: One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).
Study: NCT03174210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: liquid oxygen device (LOD)
Description: This oxygen Supplementation is used in special order

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: liquid oxygen device (LOD)
Description: This oxygen Supplementation is used in special order

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable oxygen concentrator (POC)
Description: This oxygen Supplementation is used in special order

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: portable oxygen concentrator (POC)
Description: This oxygen Supplementation is used in special order
Study: NCT03903510

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: Participants in the experimental group will receive an AppliedVR virtual reality headset during their cast removal.
Study: NCT04107727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: Induction: oral quizartinib (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral quizartinib (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral quizartinib 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Induction: oral placebo (dose defined in safety run-in phase) 14 days (8-21) (dose will be halved with strong CYP3A inhibitor), up to 2 cycles of 35 days.~Consolidation: oral placebo (dose defined in safety run-in phase) 14 days (6-19) (dose will be halved with strong CYP3A inhibitor), up to 4 cycles of 35 days.~Maintenance: oral placebo 60mg/day (dose will be halved with strong CYP3A inhibitor), up to 12 cycles of 28 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cytarabine
Description: Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Induction: Cytarabine continuous IV infusion, 200 mg/m2 (days 1-7), up to 2 cycles of 35 days.~Consolidation: Cytarabine IV infusion, 1,5-3 g/m2 (days 1, 3, 5), up to 4 cycles of 35 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Idarubicin
Description: Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idarubicin
Description: Induction: Idarubicin IV infusion 12 mg/m2 (days 1-3), up to 2 cycles of 35 days.
Study: NCT00492973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone acetate
Description: Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: active comparator
Description: bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline
Study: NCT02984592

Intervention type: BEHAVIORAL
Intervention: physical exercise
Description: regular exercise programs in the previous 6 months.
Study: NCT03244007

Intervention type: PROCEDURE
Intervention: Vitrectomy

Intervention type: PROCEDURE
Intervention: Vitrectomy
Study: NCT03029975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Exercise
Description: Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training Exercise
Description: Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beef Protein Consumption
Description: Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Beef Protein Consumption
Description: Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.
Study: NCT01703858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BI 113608 PIB
Description: powder for oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: conventional tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: conventional tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: conventional tablet formulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pantoprazole 40 mg STADA
Description: film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 113608
Description: conventional tablet formulation
Study: NCT00363038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Petrolatum United States Pharmacopeia (USP)
Description: Topical formation applied to bruise twice daily for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K and retinol ointment
Description: Topical formation applied to bruise twice daily for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arnica ointment
Description: Topical formation applied to bruise twice daily for 2 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin K ointment
Description: Topical formation applied to bruise twice daily for 2 weeks.
Study: NCT03474679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Participants will receive 420 mg (3 \* 140 mg capsules) oral ibrutinib once daily starting on Week 1 Day 1, unless they have intervening unacceptable toxicity or meet other criteria for participants discontinuation.
Study: NCT01258959

Intervention type: PROCEDURE
Intervention: Ultrasound detection of local anesthetics spread
Description: During the parabulbar injection the ultrasound operator experienced in ultrasound guided retrobulbar block will assess whether there is spread of local anaesthetic in the central cone just behind the sclera (yes or no). The anaesthesist performing the block will be blinded to the ultrasound visualized spread of local anaesthetic.
Study: NCT02456246

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FLT-PET
Description: Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
Study: NCT01242644

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pain pump containing ropivacaine
Description: 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: saline pain pump with injectable medication
Description: 30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ropivacaine, ketorolac , morphine sulfate
Description: 30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
Study: NCT00706030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Study: NCT00625443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded (placebo)
Description: Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open Label (Avatrombopag tablets)
Description: Dose 10 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinded (Avatrombopoag tablets)
Description: Dose: 2.5, 5, 10, or 20 mg~Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)~Duration - 6 months